Vect-Horus: Revolutionizing Biotechnology with Targeted Delivery Therapy at Viva Technology Conference

Vect-Horus, a biotechnology company based in Marseille, France, is set to showcase its groundbreaking technology at the Viva Technology conference in Paris from May 22-25, 2024. The company has been selected by France’s National Center for Scientific Research (CNRS) as one of ten startups with innovative technologies to present at the event.

Vect-Horus’s Chief Scientific Officer, Jean-Manuel Pean, will be part of a roundtable discussion where he will provide an overview of the company and its pipeline. He will discuss the progress made with their VECTrans® technology, the early clinical trials of their theragnostic agent for glioblastoma and pancreatic cancer, and provide updates on their partnerships with Novo Nordisk and Ionis Pharmaceuticals.

The detailed roundtable program will be announced closer to the event. Vect-Horus was founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University). They focus on developing vectors for targeting and delivering therapeutic or imaging agents to organs and tumors.

With 38 employees, predominantly in research and development, Vect-Horus continues to make strides in the biotechnology field. For more information about Vect-Horus, visit their website at www.vect-horus.com. For media inquiries or press releases, contact Vect-Horus at contact@vect-horus.com. For any other information, reach out to their Business Development and Alliance Manager, Emmanuelle Bettendorf, or the media relations team at Cohesion Bureau.